‘It's taking a healthy eye and making it sick': Columbia doctor says LASIK eye surgery is riskier than we think
Dr Cynthia MacKay, an eye surgeon at Columbia University, is one of those sounding the alarm. In a recent podcast appearance, where she was seen in conversation with YouTuber Alex Clark, she claimed that LASIK doesn't necessarily help people see better — in fact, it can leave them worse off.
Dr Mackay said, 'The FDA is not taking care of the health of the public. They are not warning about the dangers of LASIK.' She added, 'After 7-8 years, 44% of people lost the ability to see at a distance. You lose something called contrast sensitivity, which is the ability to see subtle shades of grey, and that's in 100% of the people.'
The ophthalmologist asserted that the procedure is essentially 'taking a healthy eye and making it sick,' adding that there are 'late complications' that can show up even 25 years later.' Finally, she warns, 'Don't have repeat LASIK. Many ophthalmologists feel exactly the way I do. LASIK doesn't make you see better; it always makes you see worse.'
Dr Devaprasad G, senior consultant at M.C.Modi Eye Hospital, Bangalore, tells indianexpress.com, 'From an ophthalmological standpoint, it would be inaccurate to say that LASIK universally turns a healthy eye into a sick one. However, LASIK indeed alters the corneal structure permanently. This change can, in some individuals, lead to complications such as dry eyes, night vision issues, or even visual disturbances like glare and halos. These effects vary depending on the individual's ocular anatomy, healing response, and pre-existing conditions.'
A post shared by Alex Clark (@realalexclark)
He adds that while the vast majority of patients experience improved vision and high satisfaction, LASIK is not without risks. 'Ophthalmologists must screen patients thoroughly, explain all possible outcomes, and ensure they are suitable candidates. Informed consent must go beyond immediate surgical risks to include discussions around potential long-term effects,' he stresses.
LASIK reshapes the cornea to correct refractive errors, Dr Devaprasad G states, which generally results in improved distance vision shortly after the procedure. However, as the eye naturally ages, other changes such as lens stiffening (presbyopia) or the development of cataracts may still occur, independent of LASIK. These can affect distance vision over time, but not as a direct result of the procedure itself.
'Regarding contrast sensitivity, some patients do report a mild reduction, especially under low-light conditions. While this tends to improve during the initial healing period, a small subset may notice lingering issues. Long-term studies suggest that contrast sensitivity stabilises for most people, but it is a point that should be addressed clearly during the pre-operative consultation,' explains the doctor
Though LASIK has been in use for more than two decades, extremely long-term data is still evolving. Dr Devaprasad G notes, 'Most known complications arise within the first year post-surgery, such as dry eyes, corneal ectasia, or flap-related issues. However, some delayed concerns, like progressive corneal weakening or changes in visual quality, have been observed in a small number of cases.'
What is often under-discussed is how LASIK may influence future eye care. 'For example, post-LASIK corneas can complicate cataract measurements or other surgical procedures down the line. Patients should be informed not just about the initial recovery and expected visual outcomes, but also how the procedure may shape their lifelong eye health and future interventions,' concludes Dr Devaprasad G.
DISCLAIMER: This article is based on information from the public domain and/or the experts we spoke to. Always consult your health practitioner before starting any routine.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
5 hours ago
- Time of India
How a one-minute jolt from the SetPoint implant offers new hope for autoimmune disease patients
The US Food and Drug Administration (FDA) recently approved a medical device that could bring new hope to patients suffering from rheumatoid arthritis (RA), a chronic autoimmune condition often difficult to treat with conventional medications. Unlike standard therapies, the device harnesses the brain and nervous system to suppress the uncontrolled inflammation responsible for the disease. The SetPoint System is a small, inch-long implant surgically placed in the neck, wrapping around the vagus nerve, which is thought to be the longest nerve in the body. It delivers one minute of electrical stimulation per day, which research suggests can 'reset' the immune system and reduce crippling inflammation. Unlike most RA drugs that suppress the immune system and increase infection risk, this device works by re-educating the body's immune response. Finance Value and Valuation Masterclass - Batch 4 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Finance Value and Valuation Masterclass - Batch 3 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals By Vaibhav Sisinity View Program Finance Value and Valuation Masterclass - Batch 2 By CA Himanshu Jain View Program Finance Value and Valuation Masterclass Batch-1 By CA Himanshu Jain View Program Described on a recent episode of the American College of Rheumatology podcast as a 'true paradigm shift' in RA treatment, the SetPoint implant moves away from decades of reliance on pharmaceuticals, from gold salts to biologics. The FDA had granted it breakthrough designation last year to accelerate development and approval. The device represents an early example of bioelectronic medicine, which aims to control inflammation—a key factor in conditions including diabetes, heart disease, and cancer. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like This Could Be the Best Time to Trade Gold in 5 Years IC Markets Learn More Clinical trials are already exploring vagus nerve stimulation for inflammatory bowel disease in children, lupus, multiple sclerosis, and Crohn's disease. In a yearlong randomized controlled trial involving 242 patients with a sham-treatment group, over half of participants using the implant alone achieved remission or experienced disease improvement. Joint pain and swelling decreased by 60% and 63%, respectively. However, the device's long-term safety and effectiveness outside clinical trials remain unknown, and the FDA requires post-marketing monitoring. Experts warn that surgery for implants can carry a risk of serious infections resistant to antibiotics. For Dawn Steiner, a 58-year-old speech pathologist and clinical trial participant, the implant has been transformative. Diagnosed with RA 15 years ago, she tried eight biologic drugs with limited success. 'Before the implant, the doctor would ask where I was in terms of pain on a scale of one to 10, and I would say I was living a six or seven,' she said. 'Now I'm about a two.' Live Events The SetPoint device stems from decades of research led by Dr. Kevin J. Tracey, neurosurgeon and president of the Feinstein Institutes for Medical Research at Northwell Health. Tracey co-founded SetPoint Medical and now serves as an adviser. He describes the vagus nerve as an 'on-off switch' for an overactive immune system. 'The brain can turn off inflammation as long as the vagus nerve is intact,' he said. 'It's like a brake system in your car.' Dr. David Chernoff, chief medical officer of SetPoint Medical, explained, 'Drugs find a pathway that contributes to damaging joints in RA patients and try to block it. What we're doing is completely different. We're re-educating the immune system through the brain to behave differently.' He added, 'we're not blocking the ability to fight off infection.' Tracey noted that some inflammation is necessary for healing wounds, fighting infections, and tissue repair. The device's price has not been disclosed, but a spokeswoman said it is designed to last 10 years and could cost less than a year of certain RA medications. Dr. Lou Bridges, chief of rheumatology at the Hospital for Special Surgery and NewYork-Presbyterian/Weill Cornell Medical Center, expressed cautious optimism. 'It's still early days. The proof will be in the pudding,' he said. 'I'm hoping they are correct, and this is a revolutionary new way to treat RA without drugs and without side effects. But I've heard this story before.' [With TOI inputs]
Indian Express
9 hours ago
- Indian Express
‘He's 6'3', has a swimmer's body and follows a hyperdisciplined lifestyle': What we can learn from R Madhavan's son Vedaant's 4 am routine and mindful eating habits
R Madhavan, known for his memorable performances in films like Rehnaa Hai Terre Dil Mein, 3 Idiots, and Tanu Weds Manu, recently gave fans a personal glimpse into his family life — one where the spotlight has gradually shifted to his son, Vedaant Madhavan, a champion swimmer with an extraordinary routine. In a conversation with GQ, the actor shared, 'As a professional swimmer, Vedaant's day ends at eight o'clock, and then he's up again at four in the morning. It's the most demanding part of the job, not just for him, but also for his parents. That hour is called brahma muhurta, said to be the most spiritually conducive time to wake up.' Kanikka Malhotra, a consultant dietician and certified diabetes educator, tells 'Early rising supports circadian rhythms. This leads to better sleep quality and improves cognitive function. An athletic structure fosters self-discipline, reduces stress, and improves overall well-being. This is essential for adolescent brain development and resilience against mental health challenges like anxiety and depression.' She adds, 'Mindful eating is also part of this routine. It helps with nutrient absorption and digestion, which are important for growth, metabolism, and recovery in young athletes. Such discipline can boost self-esteem, maintain energy balance, and create lifelong health habits during a critical time.' A post shared by R. Madhavan (@actormaddy) Malhotra notes that focusing on meal balance, chewing, and being present during meals 'promotes better digestion, improves nutrient absorption, and reduces gastrointestinal distress.' She mentions that this is important for athletic performance and recovery. For teens, mindful eating encourages a healthy relationship with food, helps control portion sizes, and prevents both overeating and under-fueling. This protects against energy crashes and mood swings. Mindful practices reduce distracted or stress-induced eating and foster awareness of hunger and fullness cues. Ultimately, they support optimal physical performance, recovery, and mental clarity. Creating a judgment-free environment lets children express themselves honestly and helps build their confidence. Malhotra states, 'Some practical strategies are having regular open conversations, validating a teen's feelings, and including them in setting routines and household expectations. Balancing discipline with empathy by explaining the reasons behind rules and inviting feedback strengthens mutual respect. This method helps teens see discipline as a way to motivate themselves instead of feeling controlled by others. It encourages healthy habits and resilience in a supportive home.' DISCLAIMER: This article is based on information from the public domain and/or the experts we spoke to. Always consult your health practitioner before starting any routine.
Time of India
14 hours ago
- Time of India
How a one-minute jolt can offer hope to those with auto-immune disease
The US Food and Drug Administration (FDA) approved a medical device recently that offers new hope to patients incapacitated by rheumatoid arthritis (RA), a chronic condition often resistant to treatment and usually managed with medications. The device represents a radical departure from standard care, tapping the power of the brain and nervous system to tamp down the uncontrolled inflammation that leads to the debilitating autoimmune disease. The SetPoint System is an inch-long device surgically implanted into the neck, where it sits in a pod wrapped around the vagus nerve, which some scientists believe is the longest nerve in the body. The device electrically stimulates the nerve for one minute each day. The stimulation can turn off crippling inflammation and 'reset' the immune system, research has shown. Most drugs used to treat rheumatoid arthritis suppress the immune system, leaving patients vulnerable to serious infections. On a recent episode of the American College of Rheumatology podcast, the SetPoint implant was described as a 'true paradigm shift' in treatment of the disease, which until now has relied almost entirely on an evolving set of pharmaceutical interventions, from gold salts to biologics. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like No annual fees for life UnionBank Credit Card Apply Now Undo The FDA designated the implant as a breakthrough last year to expedite its development and approval. It represents an early test of the promise of so-called bioelectronic medicine to modulate inflammation, which plays a key role in diseases including diabetes, heart disease and cancer. Clinical trials are already underway testing vagus nerve stimulation to manage inflammatory bowel disease in children, lupus and other conditions. Trials for patients with multiple sclerosis and Crohn's disease are also planned. In a yearlong randomised controlled trial of 242 patients that included a sham-treatment arm, over half of the participants using the SetPoint implant alone achieved remission or saw their disease recede. Measures of joint pain and swelling fell by 60% and 63% respectively. The device's long-term effectiveness and safety outside a clinical trial are not yet known. The FDA required post-marketing monitoring of patients and adverse events as part of the approval. Surgery involving implants can lead to serious infections resistant to antibiotics, experts noted. For Dawn Steiner, 58, a speech pathologist, who participated in the clinical trial, the implant has been a game changer. She was diagnosed with rheumatoid arthritis 15 years ago and has tried eight different biologic agents since then. 'Before the implant, the doctor would ask where I was in terms of pain on a scale of one to 10, and I would say I was living a six or seven,' she said. 'Now I'm about a two.' The SetPoint device is the product of decades of research spearheaded by Dr Kevin J Tracey, a neurosurgeon who is president and chief executive of the Feinstein Institutes for Medical Research at Northwell Health. Tracey co-founded SetPoint Medical, but now serves as an adviser. He describes the vagus nerve, which originates in the brain and travels to virtually all the organs of the body, as an 'on-off switch' for an overactive immune system. 'The brain can turn off inflammation as long as the vagus nerve is intact,' he said. 'It's like a brake system in your car.' Dr David Chernoff, chief medical officer of SetPoint Medical, said, 'Drugs find a pathway that contributes to damaging joints in RA patients and try to block it. What we're doing is completely different. We're re-educating the immune system through the brain to behave differently,' he added. As a result, he said, 'we're not blocking the ability to fight off infection.' The body needs some level of inflammation, Tracey said, to help heal wounds, fight infections and promote tissue repair. The price has not been disclosed, but a spokeswoman said it was designed to last for 10 years and would be less expensive than a year's worth of some rheumatoid arthritis drugs, which can be quite costly. One key question is whether the implant's effectiveness will wane over time, said Dr Lou Bridges, chief of the division of rheumatology at the Hospital for Special Surgery and NewYork-Presbyterian/Weill Cornell Medical Center. 'It's still early days. The proof will be in the pudding,' he said. 'I'm hoping they are correct, and this is a revolutionary new way to treat RA without drugs and without side effects. But I've heard this story before. ' nyt news service By: Dr David Chernoff, CMO, SetPoint Medical
